Roger Wiprächtiger’s Post

Labcorp's most recent research, presented at the 2024 SGO Annual Meeting, highlights the crucial role of biomarker testing in guiding personalized treatments for epithelial ovarian cancer. Genomic profiling is transforming patient care, ensuring better patient outcomes through tailored therapies #precisionmedicine #cancerdiagnostics #biotouch https://hubs.li/Q02pYm3c0

⭐️KACTUS's GMP-grade base editing enzyme has played a pivotal role in contributing to the IND filling of a NK cell injection cancer therapy⭐️ Utilizing KACTUS's base editing enzyme, AccuBase™, in their NK510 cell injection Base Therapeutics moves one step closer to IND approval. This marks a significant milestone in cancer therapy, and showcases the immersive potential of GMP-grade base editors in CGT manufacturing. 🔗 Discover the full story: https://bit.ly/3WJuF8n

The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer:-

🔬 Exciting News from Gradalis Inc. 🔬 We are thrilled to announce GRAD1405, a bi-shRNAi candidate, has achieved a groundbreaking milestone by demonstrating a positive impact on three key KRAS mutations identified in drug-resistant lung, colon, and pancreatic cancers. 🌟 Key Highlights: 🎯 GRAD1405 utilizes Gradalis' breakthrough gene-silencing bi-shRNAi technology to specifically reduce the expression of mutated KRAS genes. 🚀 Existing therapies face rapid drug resistance, but GRAD1405 has shown remarkable control over tumor cell growth in resistant cancers. 💡 Gradalis' gene-silencing platform, including Vigil immunotherapy, has already proven successful in ovarian and other cancers.

“For the longest time, people thought this is not something that can be commercialized.” Chantale Bernatchez, head of Process Development at CTMC / A joint venture between Resilience + MD Anderson Cancer Center The FDA has recently approved Iovance Biotherapeutics’ tumor infiltrating lymphocyte (TIL) therapy Amtagvi® for patients with unresectable or metastatic melanoma – marking the first cell therapy of its class to target a solid tumor. In an interview with Labiotech.eu, Chantale shared her insights into TIL therapy and what the first approval means for the cell and gene therapy sector. As Amtagvi® paves the way for many more TIL therapy approvals, it is imperative that logistical and reimbursement challenges are overcome, so that these therapies are not just approvable but accessible and affordable too. Read more ➡️ https://lnkd.in/dDBfZ5PU #CellTherapy #GeneTherapy #Biotechnology #ManufacturingBrighterFutures #AdvancedTherapies

🎉Pfizer's TALZENNA® Receives Novel EU #Approval for Prostate Cancer Treatment! 🎉 ℹ Pfizer's oral PARP inhibitor, TALZENNA®, in combination with XTANDI®, has been approved by the #europeancommission for metastatic castration-resistant prostate cancer (mCRPC). This marks the #first and only PARP inhibitor licensed in the EU for use with XTANDI for patients with mCRPC, with or without gene mutations. The approval is based on data from the Phase III TALAPRO-2 trial, which showed that TALZENNA plus XTANDI reduced the risk of disease progression or death by 37 percent versus placebo plus XTANDI. The #combination offers an effective #treatment that addresses disease progression in patients with or without any specific gene mutation. 💡 This significant advancement underscores Pfizer's #commitment to providing #innovative treatments for patients with prostate #cancer. #Pfizer #TALZENNA #XTANDI #ProstateCancer #innovation #EUApproval #medicaladvancements #cancertreatment #SymmetricTraining

Tumor patients with mutant RAS possess a worse prognosis and shorter overall survival compared with those patients without RAS mutation. Emerging strategies have been recently developed for RAS-targeting therapy. This blog post explores the ‘undruggable’ oncology target RAS, inhibitory techniques used on downstream pathways, and the preclinical models available to test up-and-coming RAS targeted agents. #CancerResearch #Oncology

Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic #stockmarket #stocks #investing #businessnews #trading #daytrading #clinicaltrial #AI #artificialintelligence

Tumor patients with mutant RAS possess a worse prognosis and shorter overall survival compared with those patients without RAS mutation. Emerging strategies have been recently developed for RAS-targeting therapy. This blog post explores the ‘undruggable’ oncology target RAS, inhibitory techniques used on downstream pathways, and the preclinical models available to test up-and-coming RAS targeted agents. #CancerResearch #Oncology

Tumor patients with mutant RAS possess a worse prognosis and shorter overall survival compared with those patients without RAS mutation. Emerging strategies have been recently developed for RAS-targeting therapy. This blog post explores the ‘undruggable’ oncology target RAS, inhibitory techniques used on downstream pathways, and the preclinical models available to test up-and-coming RAS targeted agents. #CancerResearch #Oncology